- Home
- AKBA vs DSM Comparison
AKBA vs DSM Comparison
Compare AKBA & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKBA | DSM |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 298.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AKBA | DSM |
|---|---|---|
| Price | $1.22 | $5.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.67 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 135.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $5.46 |
| 52 Week High | $3.81 | $6.30 |
Technical Indicators
Market Signals| Indicator | AKBA | DSM |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 26.15 |
| Support Level | $1.16 | $5.80 |
| Resistance Level | $1.52 | $6.21 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 7.59 | 5.56 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.